- Home
- LICN vs BJDX Comparison
LICN vs BJDX Comparison
Compare LICN & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- BJDX
- Stock Information
- Founded
- LICN 2004
- BJDX 2015
- Country
- LICN China
- BJDX United States
- Employees
- LICN N/A
- BJDX N/A
- Industry
- LICN
- BJDX Medical Specialities
- Sector
- LICN
- BJDX Health Care
- Exchange
- LICN Nasdaq
- BJDX Nasdaq
- Market Cap
- LICN 2.1M
- BJDX 2.2M
- IPO Year
- LICN 2023
- BJDX 2021
- Fundamental
- Price
- LICN $3.31
- BJDX $1.75
- Analyst Decision
- LICN
- BJDX
- Analyst Count
- LICN 0
- BJDX 0
- Target Price
- LICN N/A
- BJDX N/A
- AVG Volume (30 Days)
- LICN 50.3K
- BJDX 414.0K
- Earning Date
- LICN 01-01-0001
- BJDX 05-19-2025
- Dividend Yield
- LICN N/A
- BJDX N/A
- EPS Growth
- LICN N/A
- BJDX N/A
- EPS
- LICN N/A
- BJDX N/A
- Revenue
- LICN $41,477,000.00
- BJDX N/A
- Revenue This Year
- LICN N/A
- BJDX N/A
- Revenue Next Year
- LICN N/A
- BJDX $55.56
- P/E Ratio
- LICN N/A
- BJDX N/A
- Revenue Growth
- LICN 4.32
- BJDX N/A
- 52 Week Low
- LICN $0.04
- BJDX $1.46
- 52 Week High
- LICN $7.55
- BJDX $316.80
- Technical
- Relative Strength Index (RSI)
- LICN 45.62
- BJDX 40.54
- Support Level
- LICN $3.26
- BJDX $1.66
- Resistance Level
- LICN $3.96
- BJDX $2.33
- Average True Range (ATR)
- LICN 0.39
- BJDX 0.20
- MACD
- LICN -0.03
- BJDX 0.05
- Stochastic Oscillator
- LICN 3.64
- BJDX 33.33
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.